You are here

  • Home
  • Archive
  • Volume 75, Issue 10
  • Infliximab and CT-P13 immunogenicity assessment in PLANETAS and PLANETRAS main and extension studies: utility of laboratory methods description

Article Text

Article menu

Download PDFPDF

Electronic pages
Correspondence
Infliximab and CT-P13 immunogenicity assessment in PLANETAS and PLANETRAS main and extension studies: utility of laboratory methods description
Free
  1. Francesca Meacci1,
  2. Mariangela Manfredi1,
  3. Maria Infantino1,
  4. Valentina Grossi1,
  5. Maurizio Benucci2
  1. 1Immunology and Allergology Laboratory, San Giovanni di Dio Hospital, Florence, Italy
  2. 2Rheumatology Unit, San Giovanni di Dio Hospital, Florence, Italy
  1. Correspondence to Dr Francesca Meacci, Immunology and Allergology Laboratory, San Giovanni di Dio Hospital, via di Torre Galli 1, Firenze 50143, Italy; francesca.meacci{at}uslcentro.toscana.it

https://doi.org/10.1136/annrheumdis-2016-210078

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Immunogenicity is known to be one of the main parameters to be considered during evaluation of the safety and efficacy of a biologic drug. The recent introduction in rheumatologic therapy of biosimilar drugs requires the comparison to the correspondent reference product (RP) of all their characteristics, included immunogenicity. In particular, immunogenicity of infliximab (IFX) biosimilar CT-P13 and IFX-RP …

    View Full Text

    Linked Articles